Baughn, Linda B. http://orcid.org/0000-0001-5229-4897
Jessen, Erik
Sharma, Neeraj http://orcid.org/0000-0002-8229-3083
Tang, Hongwei
Smadbeck, James B.
Long, Mark D.
Pearce, Kathryn
Smith, Matthew
Dasari, Surendra
Sachs, Zohar http://orcid.org/0000-0001-9386-4163
Linden, Michael A.
Cook, Joselle http://orcid.org/0000-0001-5335-9533
Keith Stewart, A.
Chesi, Marta http://orcid.org/0000-0002-4024-8225
Mitra, Amit http://orcid.org/0000-0003-4046-7070
Leif Bergsagel, P. http://orcid.org/0000-0003-1523-7388
Van Ness, Brian http://orcid.org/0000-0003-4985-2274
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 CA224018)
Article History
Received: 27 November 2022
Revised: 26 April 2023
Accepted: 2 May 2023
First Online: 22 May 2023
Competing interests
: SKK served as a consultant for Celgene, Takeda, Amgen, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Takeda, Novartis, Amgen, AbbVie, Janssen, and Bristol-Myers Squibb. A.K.S. received support from Amgen, Glaxo Smith Klein, Genentech, Janssen, Ono, Skyline Diagnostics, and Tempus Labs, Inc. LBB serves as consultant for Genentech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.